Nowadays, some various chemical markers, including prostatic specific antigen (PSA), are being used to screen PC; however, none of these markers have sufficient sensitivity and specificity for prognosis evaluation (5, 6). This evidence concerns the gene KLK3 and pachyonychia congenita.